Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601848 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00601848 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 9 participants.
The verdict
NCT00601848, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy given during surgery works in treating patients with resectable non-small cell lung cancer that has spread to the pleura.
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- DRUG chemotherapy
- DRUG porfimer sodium
- PROCEDURE spectroscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601848
The ClinicalTrials.gov registry entry for NCT00601848 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00601848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601848 about?
NCT00601848 is a clinical study titled "Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura". RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery. ...
What is the current status of trial NCT00601848?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00601848?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), chemotherapy (DRUG), porfimer sodium (DRUG), spectroscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00601848?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.